Retatrutide Starting Dose: What Clinical Trial Data Tells Us

Retatrutide is an investigational triple receptor agonist generating significant scientific interest for the treatment of obesity and type 2 diabetes. Understanding how much retatrutide to start is an important question, particularly as Phase 2 trial data have shown promising results. Based on published clinical trial protocols, initiation was typically at 2 mg once weekly via subcutaneous injection, with gradual dose escalation over several months. However, retatrutide has not yet received MHRA marketing authorisation and remains unavailable outside of regulated clinical trials. This article explains the trial dosing approach, escalation schedules, relevant safety considerations, and how to access legitimate research opportunities in the UK.

What Is Retatrutide and How Does It Work?

Retatrutide is an investigational triple receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors, aiming to reduce appetite, stimulate insulin secretion, and increase energy expenditure. It remains unlicensed and under Phase 3 clinical investigation.

Retatrutide is an investigational injectable medicine being developed primarily for the treatment of obesity and type 2 diabetes. It belongs to a novel class of agents known as triple receptor agonists, meaning it is designed to simultaneously activate three distinct hormone receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor. This triple mechanism of action distinguishes retatrutide from existing approved therapies such as semaglutide (a GLP-1 receptor agonist) or tirzepatide (a dual GIP/GLP-1 receptor agonist).^[5][10]

By activating the GLP-1 receptor, retatrutide is thought to stimulate insulin secretion in a glucose-dependent manner, suppress glucagon release, and reduce appetite. The role of GIP receptor activation in humans remains an active area of research; preclinical data have suggested possible contributions to appetite regulation, but the extent to which these effects translate to people is not yet established. The addition of glucagon receptor agonism is a distinguishing feature: preclinical evidence and early human data suggest it may increase energy expenditure and promote fat breakdown (lipolysis), though these mechanisms are considered hypotheses pending further human investigation, and the precise contribution of each receptor in people remains under study.

In a Phase 2 clinical trial published in the New England Journal of Medicine (2023), retatrutide demonstrated substantial reductions in body weight in adults with obesity but without type 2 diabetes. At the highest dose explored (12 mg once weekly), mean weight loss of approximately 24% of body weight was observed over 48 weeks in that dose group. These results reflect a specific dose arm within a defined obesity cohort and may not apply across all doses, populations, or indications such as type 2 diabetes. Nonetheless, the findings have generated considerable scientific interest.

It is important to note that retatrutide has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA), and it remains under clinical investigation.^[7] It should not be confused with currently licensed weight management medicines available in the UK.

Recommended Starting Dose of Retatrutide

Phase 2 trial protocols typically initiated retatrutide at 2 mg once weekly via subcutaneous injection, allowing gradual adaptation before dose escalation. This is not an approved prescribing dose, as retatrutide holds no MHRA marketing authorisation.

Based on Phase 2 clinical trial protocols conducted by Eli Lilly, initiation was typically at 2 mg administered once weekly via subcutaneous injection.^[1][2] This low introductory dose is intentional: it allows the body to gradually adapt to the drug's pharmacological effects before the dose is escalated. Exact dosing schedules varied between trial cohorts and protocols; 2 mg once weekly represents the most commonly reported starting point in published Phase 2 data (including the NEJM 2023 obesity trial and associated type 2 diabetes study), not a universally fixed starting dose.

The once-weekly subcutaneous injection format mirrors the administration route of other GLP-1-based therapies already familiar to clinicians and patients, such as semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro). The injection is typically administered into the abdomen, thigh, or upper arm, rotating sites to minimise local skin reactions.

Because retatrutide does not currently hold MHRA marketing authorisation, there is no approved Summary of Product Characteristics (SmPC) and no NICE appraisal or guidance for this medicine. The dosing information presented here is derived exclusively from clinical trial protocols and published research literature, and should not be interpreted as prescribing advice. Patients should not attempt to source or self-administer retatrutide outside of a regulated clinical trial setting. Doing so carries significant safety risks, including exposure to counterfeit or unregulated substances, unknown drug interactions, and the absence of appropriate medical supervision. If you are interested in accessing retatrutide, the only legitimate and safe route is through a registered clinical trial.

How the Dose Is Gradually Increased Over Time

Retatrutide was escalated stepwise in trials: 2 mg (weeks 1 to 4), 4 mg (weeks 5 to 8), 8 mg (weeks 9 to 12), then up to 12 mg once weekly thereafter, with pauses permitted if gastrointestinal side effects occurred.

In clinical trial protocols, retatrutide followed a structured dose-escalation schedule designed to minimise gastrointestinal side effects, the most commonly reported adverse effects with this class of medication. After initiating treatment at 2 mg once weekly, the dose was typically increased in a stepwise fashion over several months. Escalation schedules varied between trial cohorts; some participants took longer to reach higher doses depending on tolerability and protocol design.

One example escalation schedule, drawn from the Phase 2 obesity trial published in the NEJM (2023) and its supplementary appendix, proceeded broadly as follows:

• Weeks 1 to 4: 2 mg once weekly (initiation phase)

• Weeks 5 to 8: 4 mg once weekly

• Weeks 9 to 12: 8 mg once weekly

• Weeks 13 onwards: Up to 12 mg once weekly (the maximum dose explored in Phase 2 trials)

This is an illustrative example from one trial arm only; actual schedules in individual trial arms varied. This information is provided for educational context and does not constitute dosing guidance.

This gradual titration approach is consistent with the prescribing philosophy applied to other incretin-based therapies in the UK, where slow escalation is used to improve tolerability and encourage long-term adherence. Participants who experienced significant nausea, vomiting, or other gastrointestinal symptoms during escalation could have their dose increase paused or delayed until symptoms resolved.

The highest doses studied, 8 mg and 12 mg, were associated with the greatest weight loss outcomes in trial data, but also with a higher incidence of side effects. Clinicians overseeing trial participants assessed each individual's response and tolerability before proceeding to the next dose level. This individualised approach to titration is an important safety feature and underscores why retatrutide must only be used under close medical supervision within an approved research framework.

Factors That May Affect Your Starting Dose

Starting dose and escalation speed in trials were influenced by BMI, renal and hepatic function, gastrointestinal history, concomitant glucose-lowering medications, and age, with all adjustments determined by the supervising trial clinician.

Although retatrutide is not yet available outside of clinical trials, the factors that influence starting dose and titration speed are broadly consistent with those applied to similar licensed medicines. Understanding these factors is useful for patients who may be considering participation in a trial or who wish to discuss emerging therapies with their healthcare provider.

Body weight and BMI play a role in determining eligibility for weight management trials, with most retatrutide studies enrolling adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above in the presence of weight-related comorbidities such as hypertension or dyslipidaemia, consistent with the inclusion criteria described in published Phase 2 protocols and ClinicalTrials.gov records for retatrutide studies.

Renal and hepatic function are important considerations. Human pharmacokinetic data for retatrutide are limited at this stage; however, patients with significant kidney or liver disease may be at greater risk of complications from gastrointestinal side effects such as dehydration, and would typically require closer monitoring. Any adjustments to escalation schedules would be protocol-specific and determined by the trial clinician.

Gastrointestinal history is also relevant. Individuals with severe gastroparesis or significant gastrointestinal disease may be at greater risk of exacerbated symptoms and would need careful individual assessment before commencing treatment.

Concomitant medications, particularly other glucose-lowering agents such as insulin or sulphonylureas, may increase the risk of hypoglycaemia when used alongside retatrutide. People taking these medicines may require dose adjustments to their existing treatments under medical supervision.

Typical trial exclusion criteria for retatrutide studies, as described in published Phase 2 protocols, have included: pregnancy or breastfeeding (with active contraception requirements during participation); a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2); and a history of pancreatitis. These exclusions reflect established class safety considerations.

Age and frailty may also influence tolerability. Older adults or those with reduced physiological reserve may benefit from a more cautious escalation approach. All of these factors would be assessed by a trial clinician prior to enrolment and throughout the treatment period.

Side Effects to Be Aware of When Beginning Treatment

The most common side effects of retatrutide are gastrointestinal, particularly nausea, vomiting, and diarrhoea, especially during initiation and escalation. Serious but less common risks include pancreatitis, gallbladder disease, and increased heart rate.

As with other GLP-1-based therapies, the most frequently reported side effects of retatrutide, particularly during the initiation and dose-escalation phases, are gastrointestinal in nature. These include:

• Nausea (the most common complaint, particularly in the first few weeks)

• Vomiting

• Diarrhoea or constipation

• Decreased appetite (which, while therapeutically desirable, can occasionally be excessive)

• Abdominal discomfort or bloating

• Injection-site reactions (such as redness, itching, or mild swelling at the injection site)

• Headache, dizziness, and fatigue, particularly during early treatment

These effects are generally dose-dependent and tend to diminish as the body adjusts to the medication. Eating smaller, lower-fat meals and avoiding lying down immediately after eating can help manage nausea during the early weeks of treatment. Persistent vomiting or diarrhoea can lead to dehydration; it is important to maintain adequate fluid intake and to seek medical advice if symptoms are severe or prolonged.

More serious but less common adverse effects observed in trials or associated with this drug class include:

• Increased heart rate, a class effect seen with GLP-1 receptor agonists^[15][12]

• Gallbladder disease, including gallstones (cholelithiasis), which has been associated with rapid weight loss and incretin-based therapies more broadly.^[14][15] Symptoms may include pain in the upper right abdomen, fever, or yellowing of the skin or eyes (jaundice); seek prompt medical attention if these occur.

• Pancreatitis: although a direct causal relationship has not been confirmed, a potential signal has been observed with this drug class. Severe, persistent abdominal pain, particularly if it radiates to the back and is accompanied by vomiting, should be treated as a medical emergency. Stop treatment and seek urgent care immediately.

Preclinical studies in rodents have identified a potential signal for thyroid C-cell tumours with GLP-1 receptor agonists; this has not been demonstrated in humans, and the relevance to people is uncertain.^[17][18] As a precaution, individuals with a personal or family history of medullary thyroid carcinoma or MEN2 are typically excluded from trials. Report any new or unusual symptoms such as a neck lump, persistent hoarseness, or difficulty swallowing to your trial team promptly.

For people with diabetes, rapid improvement in blood glucose control may occasionally be associated with transient worsening of diabetic retinopathy.^[20][21] Report any new visual symptoms to your trial team or eye care provider.

If you are participating in a clinical trial and experience any severe or persistent symptoms, contact your trial team immediately. In an emergency, call 999. For urgent non-emergency advice, contact NHS 111.

If you believe you have experienced a side effect from a medicine you are taking outside of a clinical trial, you can report it to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. If you are enrolled in a clinical trial, suspected adverse reactions should be reported to your trial team or study sponsor in accordance with the trial protocol.

Current Availability and Prescribing Status in the UK

Retatrutide is not licensed in the UK and cannot be legally prescribed outside of a registered clinical trial. The only safe route to access it is through a regulated trial, searchable via the NIHR Be Part of Research service or ClinicalTrials.gov.

As of the time of writing, retatrutide is not licensed for use in the United Kingdom. It has not received marketing authorisation from the MHRA, and no MHRA-approved SmPC exists for this medicine.^[7] It has not been appraised by NICE for use within the NHS. The drug remains in clinical development, with Phase 3 trials ongoing under Eli Lilly's research programme. Current trial status and protocol details can be verified via ClinicalTrials.gov, the EU Clinical Trials Information System (CTIS), or the ISRCTN registry. Until Phase 3 trials are completed and regulatory submissions are reviewed, retatrutide cannot be legally prescribed or dispensed through standard NHS or private prescribing channels in the UK.

Patients who are interested in accessing retatrutide may wish to explore whether they are eligible to participate in a registered clinical trial. In the UK, the NIHR 'Be Part of Research' service (bepartofresearch.nihr.ac.uk) is a helpful starting point for finding legitimate clinical trials. Information is also available through ClinicalTrials.gov and the ISRCTN registry, or by speaking with a specialist obesity medicine physician or endocrinologist. Participation in a clinical trial is the only legitimate and safe route to accessing retatrutide at this stage.

It is important to be aware that some online platforms and unregulated suppliers may advertise retatrutide or similar peptides for sale. Purchasing medicines from unregulated sources is illegal, potentially dangerous, and offers no guarantee of product quality, purity, or safety. The MHRA actively warns against sourcing prescription-only medicines outside of regulated supply chains; further guidance is available on the MHRA website.

For patients seeking licensed weight management options in the UK, treatments that have received NICE appraisal include semaglutide (Wegovy) for the management of overweight and obesity, and tirzepatide (Mounjaro) for weight management, both subject to specific eligibility criteria. It should be noted that semaglutide (Ozempic) is licensed for the treatment of type 2 diabetes, not for weight management.^[10][12] NHS access to NICE-appraised anti-obesity medicines also depends on local commissioning arrangements, integrated care board (ICB) pathways, and product supply; a GP or specialist can advise on current local availability and the most suitable treatment based on individual clinical circumstances.

Frequently Asked Questions